Brief: Gubra Starts Phase 1/2A Clinical Trial Of GUB-UCN2 In Obesity
28/07/2026 06:02
BRIEF-Gubra Starts Phase 1/2A Clinical Trial Of GUB-UCN2 In Obesity July 28 (Reuters) - Gubra A/S GUBRA.CO:
ANNOUNCES INITIATION OF AMBITIOUS PHASE 1/2A CLINICAL TRIAL OF LEAD ASSET GUB-UCN2 IN OBESITY
PHASE 1/2A TRIAL TO EXPLORE GUB-UCN2 ACROSS MULTIPLE INDICATIONS
PHASE 1/2A TRIAL TO EVALUATE SAFETY AND EFFICACY OF GUB-UCN2
TRIAL WILL INVESTIGATE GUB-UCN2 AS BOTH A STANDALONE THERAPY AND IN COMBINATION WITH INCRETIN-BASED THERAPY FOR OBESITY
INITIAL SAD STUDY DATA EXPECTED IN FIRST HALF OF 2027
Source text: ID:nMFNMlgwc
Further company coverage: GUBRA.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))